Latest news
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 04:31:46 GMTHERTHENA-Breast02 Trial: Innovative Dual-ADC Strategy in HR+/HER2-Low Breast Cancer - OncodailyOncodaily · Sat, 08 Aug 2026 11:14:59 GMTLigaChem Biosciences Takes Solo Control of ADC Cancer Drug After NextCure's Strategic Pivot - finance.biggo.comfinance.biggo.com · Fri, 07 Aug 2026 06:05:00 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - Business WireBusiness Wire · Tue, 04 Aug 2026 00:00:00 GMTCombination of targeted therapies could help overcome treatment resistance in advanced prostate cancer - UCLA HealthUCLA Health · Mon, 03 Aug 2026 17:14:14 GMTFDA Fast Track and Priority Review Designations Granted in July 2026 - Oncology News CentralOncology News Central · Mon, 03 Aug 2026 13:59:35 GMTBefore the Hype: Five Early-Stage ADC Startups to Watch - Inside Precision MedicineInside Precision Medicine · Sat, 01 Aug 2026 10:40:57 GMT